Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial ...

The therapy is the fourth clinical-stage programme derived from the company’s chemoproteomics discovery platform.

San Diego, California Friday, April 4, 2025, 16:00 Hrs [IST] ...

Vividion Therapeutics, Inc. has announced that the first patient has been dosed in a Phase I clinical trial evaluating ...

VVD-159642, Vividion's fourth clinical-stage program stemming from its chemoproteomics discovery platform, is designed to improve patient outcomes by inhibiting RAS-PI3Ka, a key signaling pathway ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ... In this study, the researchers used RAS(ON) multi-selective inhibitors ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

There is sad news in sporting circles today, in the year that Meath prepares to again host the final stage of the Rás ...